About: Susan D Richman

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Susan D Richman Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	researcher (en) 연구원 (ko) 研究者 (ja) дослідниця (uk) باحت (ary) изилдөөчү (ky) 研究者 (zh) հետազոտող (hy) onderzoeker (nl) researcher (en-ca) researcher (en-gb) hulumtuese (sq) ricercatrice (it)
rdfs:label	Susan D Richman (cy) Susan D Richman (en) Susan D Richman (es) Susan D Richman (nl) Susan D Richman (sl) Susan D Richman (en-gb) Susan D Richman (ast) Susan D. Richman (it)
skos:prefLabel	Susan D Richman (cy) Susan D Richman (en) Susan D Richman (es) Susan D Richman (nl) Susan D Richman (sl) Susan D Richman (en-gb) Susan D Richman (ast) Susan D. Richman (it)
name	Susan D Richman (cy) Susan D Richman (en) Susan D Richman (es) Susan D Richman (nl) Susan D Richman (sl) Susan D Richman (en-gb) Susan D Richman (ast) Susan D. Richman (it)
affiliation	wds:Q49251838-22ad3b96-4648-de36-67ff-f80b27527dac
affiliation	Leeds Institute of Cancer and Pathology
Scopus author ID	wds:Q49251838-31f3cc0d-47f6-f161-9158-e0cbbd99d665
Scopus author ID	36973502600
given name	wds:Q49251838-7A1BFA97-B843-4BD1-B379-4668393D80B2
given name	Susan
instance of	wds:Q49251838-35169EC9-C6CD-450F-ABF9-64E7A8299CA5
instance of	Homo sapiens
doctoral student	wds:Q49251838-946C4F22-1842-45C6-9BE7-DF6CB3914B36
doctoral student	Jennifer Frances Seligmann
skos:altLabel	Susan Richman (en)
occupation	wds:Q49251838-64db4a64-4f99-584d-26bb-3733c92488be
employer	wds:Q49251838-e17683d6-427f-5083-c3bf-c8d3e643cf6b
NUKAT ID	wds:Q49251838-2AC4B07F-2D2B-4477-AD06-C0E86240A643
sex or gender	wds:Q49251838-870b4ecb-413d-5a5f-7c70-04546060a1e0
VIAF ID	wds:Q49251838-472E1366-9F08-46C6-8608-021919CE110A
family name	wds:Q49251838-5FB4FB7C-621F-4976-8E1F-9DF150065C6C
WorldCat Identities ID (superseded)	wds:Q49251838-E0C64CAB-2449-4D91-800F-50EA30A020F7
official website	wds:Q49251838-c50bd45e-4516-65cc-171e-e1256a93f7ea
VIAF ID	http://viaf.org/viaf/177148207842700341331
occupation	researcher
employer	University of Leeds
NUKAT ID	n2016088307
sex or gender	female organism
VIAF ID	177148207842700341331
family name	Richman
WorldCat Identities ID (superseded)	viaf-177148207842700341331
official website	https://medhealth.leeds.ac.uk/profile/900/813/dr_susan_richman/2
Springer Nature person ID	wds:Q49251838-42336038-1556-41E0-B69B-368133CDC356
ORCID iD	wds:Q49251838-C881F03B-14A9-4441-83D2-8778903013D4
Dimensions author ID	wds:Q49251838-debbba08-43b3-b276-a762-d49313c07de6
ORCID iD	https://orcid.org/0000-0003-3993-5041
Springer Nature person ID	01043462267.33
ORCID iD	0000-0003-3993-5041
Dimensions author ID	01043462267.33
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q49251838
is author of	KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. MLH1 −93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial Prediction of the response of colorectal cancer to systemic therapy A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival Left and right sided large bowel cancer Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial Standardising RNA profiling based biomarker application in cancer-The need for robust control of technical variables Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer. How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009-2016). Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer Artificial intelligence for detection of microsatellite instability in colorectal cancer-a multicentric analysis of a pre-screening tool for clinical application Failure to validate toxicity and outcome biomarkers from the FFCD 2000-05 trial in the MRC CR08 FOCUS trial Results of the UK NEQAS for Molecular Genetics reference sample analysis Exploring outcomes of RAS-mutant (RAS mut) advanced colorectal cancer (aCRC) treated with chemotherapy: Analysis from 2254 patients (pts) in randomised clinical trials (RCTs)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software